Core Points - The company, Bluefeng Biochemical (002513.SZ), announced a significant share reduction by its shareholder Hainan Wenqin [1] Group 1 - Hainan Wenqin reduced its holdings by 7,496,000 shares through a block trade, representing 2.00% of the company's total share capital [1] - Following the reduction, Hainan Wenqin's shareholding decreased from 33,589,000 shares to 26,093,000 shares [1] - The percentage of total share capital held by Hainan Wenqin fell from 8.95% to 6.95% [1]

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-045 江苏蓝丰生物化工股份有限公司 关于持股5%以上股东减持股份触及1%整数倍的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 江苏蓝丰生物化工股份有限公司（简称"公司"）于 2025 年 7 月 30 日在巨潮 资讯网（http://www.cninfo.com.cn）披露了《关于持股 5%以上股东减持股份预 披露公告》（公告编号：2025-035），公司股东海南闻勤私募基金管理合伙企业（有 限合伙）——闻勤顺为 1 号私募证券投资基金（以下简称"海南闻勤"）拟减持公 司股份不超过 9,795,589 股，不超过公司总股本的 2.61%，其中：以集中竞价交易 方式减持的股份数量不超过公司总股本的 1%，以大宗交易方式减持的股份数量不 超过公司总股本的 2%。 近日，公司收到股东海南闻勤出具的《股东减持股份触及 1%整数倍告知函》， 海南闻勤于 2025 年 9 月 4 日通过大宗交易方式减持公司股份 7,496,000 股，占公 司总股本的 2.00%。本次减持后，海南闻勤持有公司的股份由 ...

Group 1 - The core point of the article is that Hainan Wenqin, a shareholder of Lanfeng Biochemical, reduced its stake in the company through a block trade on September 4, 2025, selling 7.496 million shares, which accounts for 2.00% of the total share capital [1] - After the reduction, Hainan Wenqin's shareholding decreased from 33.589 million shares to 26.093 million shares, resulting in a decrease in ownership percentage from 8.95% to 6.95%, which has reached the 1% threshold [1] - As of the announcement date, the reduction plan has not been fully implemented [1]

Group 1 - The core transaction involved 7.496 million shares of Bluestar Bio, with a total transaction value of 38.0047 million yuan, accounting for 39.16% of the total trading volume on that day [1][2] - The transaction price was 5.07 yuan per share, which represents a discount of 1.55% compared to the market closing price of 5.15 yuan [1][2]

Core Viewpoint - Jiangsu Lanfeng Bio-chemical Co., Ltd. has signed a settlement and debt waiver agreement with its controlling shareholder, Jiangsu Suhua Group Co., Ltd., to resolve investor litigation and debt issues, which is expected to alleviate the company's debt pressure and optimize its capital structure [1][7]. Summary by Sections Overview of the Settlement and Debt Waiver - The company faced investor lawsuits due to information disclosure violations, resulting in a compensation requirement of RMB 22,766,475.6, including overdue interest and litigation costs [2]. - As of July 31, 2025, the company owed Jiangsu Suhua Group a total of RMB 83,600,036.66, comprising RMB 59,200,719.70 in principal and RMB 24,399,316.96 in interest [2]. - The company has reached a settlement with Jiangsu Suhua Group regarding the investor lawsuits and debt waiver [2]. Key Terms of the Agreement - Jiangsu Suhua Group will bear a total compensation responsibility of RMB 17,157,200.73 for the investor lawsuits, which will be deducted from the company's outstanding loans to the group [5]. - The agreement includes a waiver of RMB 6,000,000 in interest debt by Jiangsu Suhua Group, which is unconditional and irrevocable [5]. - Following the agreement, the company will not pursue any further claims related to the investor lawsuits against Jiangsu Suhua Group or its management [6]. Impact of the Agreement on the Company - The total amount involved in the settlement and debt waiver is RMB 23,157,200, which will help reduce the company's debt burden and improve its asset-liability structure [7]. - The company will adjust its liabilities according to relevant accounting standards based on the audit results [7].

Group 1 - The board of directors of Jiangsu Lanfeng Biological Chemical Co., Ltd. held its 26th meeting on September 3, 2025, via communication methods, with all 8 directors present [1][2] - The board approved the signing of a settlement and debt waiver agreement with Jiangsu Suhua Group Co., Ltd., which is expected to alleviate the company's debt pressure and optimize its asset-liability structure [1] - The agreement does not constitute a related party transaction and does not harm the interests of minority shareholders [1]

Group 1 - The company announced that it will hold the 26th meeting of the 7th Board of Directors on September 3, 2025 [1] - The company approved the proposal regarding the signing of a settlement and debt waiver agreement [1] - The settlement and debt waiver agreement was reached with the former controlling shareholder, Jiangsu Suhua Group Co., Ltd., concerning investor litigation claims and debt waiver [1]

（文章来源：证券日报） 证券日报网讯 9月3日晚间，蓝丰生化发布公告称，公司第七届董事会第二十六次会议审议通过了《关 于公司签署和解及债务豁免协议的议案》。 ...

Core Viewpoint - The company has reached a settlement agreement with its controlling shareholder, Jiangsu Suhua Group Co., Ltd., regarding investor litigation claims and debt waiver, which will alleviate the company's debt pressure and optimize its asset-liability structure [1] Summary by Relevant Sections Settlement Agreement - The company convened its 26th meeting of the 7th Board of Directors on September 3, 2025, to approve the signing of a settlement and debt waiver agreement [1] - The total amount involved in the settlement and debt waiver agreement is 23.1572 million yuan [1] Financial Impact - The signing of the agreement is expected to reduce the company's debt burden and improve its financial structure [1] - The company will adjust the liabilities that have been accrued in accordance with relevant provisions of the Enterprise Accounting Standards, with specific amounts to be determined based on audit results [1]

Core Viewpoint - The company has reached a settlement agreement with its controlling shareholder, Jiangsu Suhua Group Co., Ltd., regarding investor litigation claims and debt waiver, which will alleviate the company's debt pressure and optimize its capital structure [1] Summary by Relevant Sections - **Settlement Agreement**: The company signed a "Settlement and Debt Waiver Agreement" with Jiangsu Suhua Group, involving a total compensation and debt waiver amount of 23.1572 million yuan [1] - **Debt Pressure Relief**: The agreement is expected to reduce the company's debt burden and improve its asset-liability structure [1] - **Accounting Adjustments**: The company will adjust the relevant liabilities in accordance with the "Enterprise Accounting Standards," with specific amounts to be determined based on audit results [1]